Our Pricing

When Will You Notice Appetite Suppression Results?

Published on: June 03, 2026

If you're wondering how long for appetite suppressants to work UK, the answer depends on which treatment you're prescribed. GLP-1 receptor agonists like Mounjaro, Wegovy, and Saxenda typically begin reducing appetite within 1-4 weeks, though individual response varies based on dose, metabolism, and treatment type. At Cured Pharmacy, our UK prescribers help patients understand realistic timelines and optimise their weight loss journey with evidence-based guidance.

How Quickly Does Mounjaro Suppress Appetite?

Mounjaro (tirzepatide) typically begins suppressing appetite within the first 1-2 weeks of treatment, with most patients noticing significant hunger reduction by week 4 [1]. As a dual GIP/GLP-1 receptor agonist, tirzepatide works faster than single-pathway treatments by activating two complementary hormone systems that regulate satiety and gastric emptying.

In the SURPASS-1 trial, participants reported measurable appetite changes within the first month, with progressive improvement as dosing escalated [1]. Mounjaro starts at 2.5mg weekly for the first four weeks, then increases to 5mg — this gradual titration helps your body adapt whilst building therapeutic appetite control. Peak appetite suppression typically occurs between weeks 8-12 as you reach your maintenance dose.

Individual response varies based on baseline insulin sensitivity, body composition, and adherence to the dosing schedule. Some patients experience pronounced hunger reduction within days, whilst others need 3-4 weeks to notice substantial changes. Mounjaro is available from £135.00 at Cured Pharmacy, subject to prescriber approval following your free online consultation.

Wegovy and Saxenda: Appetite Suppression Timelines

Wegovy (semaglutide) generally produces noticeable appetite suppression within 2-4 weeks of starting treatment, with optimal effects emerging around week 8 as you progress through dose escalation [2]. The weekly injection schedule and gradual titration from 0.25mg to 2.4mg allows sustained GLP-1 receptor activation, slowing gastric emptying and reducing hunger signals to the brain.

Saxenda (liraglutide) works slightly faster due to its daily dosing regimen — many patients report reduced appetite within 7-14 days [3]. However, because liraglutide requires daily injections and has a shorter half-life than weekly treatments, consistent timing is critical for maintaining steady appetite control throughout the day.

Clinical trial data shows that semaglutide-based treatments like Wegovy produced average weight reductions of 14.9% over 68 weeks in the STEP-1 trial, with appetite suppression being the primary mechanism [2]. Liraglutide demonstrated 8% average weight loss over 56 weeks in the SCALE trial, with early appetite changes predicting long-term success [3].

Daily vs Weekly Injections: Impact on Appetite Control

Weekly GLP-1 injections like Mounjaro and Wegovy provide more stable appetite suppression across seven days, whilst daily Saxenda injections offer flexibility to adjust timing based on your eating patterns. Your UK prescriber will recommend the most suitable option based on your lifestyle, treatment goals, and medical history during your clinical assessment.

What Affects How Long for Appetite Suppressants to Work UK?

Several physiological factors influence appetite suppression timelines. Baseline metabolic health plays a significant role — patients with higher insulin resistance may experience slower initial response as the body adapts to improved glucose regulation [4]. Body mass index also correlates with response time, with some studies showing that individuals with BMI over 35 may need slightly longer to achieve peak appetite control.

Medication adherence and proper injection technique directly impact results. GLP-1 treatments must be administered consistently at the same time each week (or day for Saxenda) to maintain therapeutic blood levels. Missing doses or irregular timing disrupts the steady-state concentration needed for optimal appetite suppression.

Dietary composition during the first month matters more than many patients realise. High-protein meals amplify GLP-1's satiety signals, whilst ultra-processed foods can partially override appetite suppression mechanisms. Our clinical team at Cured Pharmacy provides tailored dietary guidance alongside your prescription to maximise early response.

Dose Escalation and Appetite Control

All GLP-1 treatments start at sub-therapeutic doses to minimise gastrointestinal side effects, then gradually increase over 4-20 weeks depending on the medication. This means appetite suppression strengthens progressively — the initial weeks provide moderate hunger reduction, whilst maintenance doses deliver full therapeutic effect. Patience during titration is essential for long-term success and tolerability.

Realistic Expectations: Week-by-Week Appetite Changes

Week 1-2: Most patients notice subtle changes like feeling satisfied with smaller portions or reduced snacking between meals. These early signals indicate the medication is beginning to affect gastric emptying and satiety hormones, even if dramatic hunger suppression hasn't occurred yet.

Week 3-4: Appetite reduction becomes more pronounced. Many patients report forgetting to eat or feeling genuinely uninterested in food for the first time in years. This phase often coincides with the first measurable weight loss, typically 2-4% of baseline body weight [1][2].

Week 8-12: Peak appetite suppression emerges as you reach therapeutic maintenance doses. At this stage, clinical trials show patients consume 20-35% fewer calories daily without conscious restriction [4]. Cravings for high-calorie foods diminish significantly, and portion control becomes effortless rather than willpower-dependent.

Beyond 12 weeks: Appetite suppression stabilises at a sustainable level. Some patients experience slight tolerance, though this is uncommon with proper dosing. Long-term success depends on combining pharmacological appetite control with behavioural changes — the medication creates the physiological space for healthier habits to take root.

Orlistat and Mysimba: Different Appetite Mechanisms

Not all weight loss treatments work through appetite suppression. Orlistat (available as generic, Xenical, Alli, and Orlos) blocks fat absorption in the intestine rather than reducing hunger — patients typically notice digestive changes within 24-48 hours of the first dose, but appetite remains unchanged [5]. Orlistat works best for patients who struggle with dietary fat intake rather than portion control or cravings.

Mysimba (naltrexone/bupropion combination) affects appetite through central nervous system pathways, reducing reward-driven eating and cravings over 4-8 weeks [6]. Unlike GLP-1 treatments that create physical fullness, Mysimba diminishes the psychological drive to eat, particularly for emotional or stress-related consumption. Peak effects typically emerge around week 12 of treatment.

Choosing between appetite suppressants and alternative mechanisms depends on your eating patterns. If you eat normal portions but struggle with high-fat foods, Orlistat may suit you better. If cravings and reward-driven eating dominate, Mysimba or GLP-1 treatments offer more targeted solutions. Your UK prescriber will assess which approach aligns with your clinical profile during consultation.

Combining Treatments for Enhanced Results

Some patients benefit from sequential or combination approaches, though this requires careful prescriber oversight. GLP-1 treatments are never combined with each other, but may be used alongside behavioural therapy or nutritional support programmes. Always discuss treatment combinations with your prescriber — never adjust medications independently.

Getting Started with Appetite Suppressant Treatment at Cured Pharmacy

All prescription weight loss treatments at Cured Pharmacy require clinical assessment by our UK-registered prescribers. The free online consultation takes under three minutes and evaluates your medical history, current medications, weight loss goals, and suitability for specific treatments. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees our clinical protocols to ensure safe, evidence-based prescribing.

Once approved, your medication is dispensed from our UK-registered pharmacy (GPhC 9012511) with discreet packaging and next-day delivery options. We provide detailed injection technique guides, storage instructions, and ongoing support throughout your treatment journey. Pricing is transparent before consultation — no hidden fees or surprise charges after prescriber approval.

Our clinical team monitors your progress through follow-up assessments, adjusting doses based on your response and tolerability. If appetite suppression doesn't meet expectations within the predicted timeframe, we work with you to identify barriers — whether medication-related, dietary, or metabolic — and optimise your treatment plan accordingly. Realistic timelines and evidence-based expectations are central to successful long-term weight management.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and timelines presented reflect average clinical trial data — your personal response may differ based on health status, adherence, and other factors.